Information  X 
Enter a valid email address

Glaxosmithkline PLC Ord 25P (GSK)

Date Time Source Announcement
15 Oct 2019 5:00 pm
RNS
Director/PDMR Shareholding
  5:00 pm
RNS
Director/PDMR Shareholding
  5:00 pm
RNS
Director/PDMR Shareholding
  5:00 pm
RNS
Director/PDMR Shareholding
11 Oct 2019 5:34 pm
RNS
Director/PDMR Shareholding
  4:10 pm
RNS
Director/PDMR Shareholding
10 Oct 2019 4:18 pm
RNS
Director/PDMR Shareholding
01 Oct 2019 6:18 pm
RNS
Director/PDMR Shareholding
  1:09 pm
RNS
Total Voting Rights
30 Sep 2019 7:00 am
RNS
Data show anti-tumour activity with ICOS agonist
  7:00 am
RNS
PRIMA shows Zejula improves PFS in ovarian cancer
26 Sep 2019 6:26 pm
RNS
Director/PDMR Shareholding
17 Sep 2019 5:46 pm
RNS
Director/PDMR Shareholding
11 Sep 2019 4:30 pm
RNS
Director/PDMR Shareholding
04 Sep 2019 5:37 pm
RNS
Director/PDMR Shareholding
  12:36 pm
RNS
Director/PDMR Shareholding
  9:33 am
RNS
Director/PDMR Shareholding
02 Sep 2019 11:29 am
RNS
Total Voting Rights
23 Aug 2019 7:00 am
RNS
GSK - positive results from pivotal DREAMM-2 study
22 Aug 2019 7:00 am
RNS
ViiV results positive for every 2 month injection
21 Aug 2019 8:00 am
RNS
GSK submits regulatory file in Japan: Daprodustat
12 Aug 2019 3:45 pm
RNS
Director/PDMR Shareholding
01 Aug 2019 3:30 pm
RNS
EU approval for Nucala self-administration
  2:10 pm
RNS
Total Voting Rights
  7:00 am
RNS
GSK completes transaction with Pfizer for New JV
30 Jul 2019 3:35 pm
RNS
Director/PDMR Shareholding
29 Jul 2019 7:00 am
RNS
ViiV submits cabotegravir to EMA for HIV injection
24 Jul 2019 6:01 pm
RNS
Director/PDMR Shareholding
  4:01 pm
RNS
ViiV 2DR TANGO switch study positive at 48 weeks
  4:00 pm
RNS
ViiV GEMINI studies show high efficacy at 96 weeks
  12:07 pm
RNS
Second Price Monitoring Extn
  12:02 pm
RNS
Price Monitoring Extension
  12:00 pm
RNS
2nd Quarter Results
  10:00 am
RNS
Non-Executive Chairman
22 Jul 2019 5:00 pm
RNS
ViiV presents 96-week data from phase III study
15 Jul 2019 6:19 pm
RNS
Director/PDMR Shareholding
  6:18 pm
RNS
Director/PDMR Shareholding
  6:16 pm
RNS
Director/PDMR Shareholding
  11:42 am
RNS
Director/PDMR Shareholding
  7:00 am
RNS
positive results in Phase 3 PRIMA study of ZEJULA
12 Jul 2019 4:35 pm
RNS
Director/PDMR Shareholding
  3:55 pm
RNS
Director/PDMR Shareholding
10 Jul 2019 3:48 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
ViiV switch study shows 2DR as effective as 3DR
03 Jul 2019 9:00 am
RNS
ViiV receives Dovato EU Marketing Authorisation
01 Jul 2019 12:08 pm
RNS
Total Voting Rights
12 Jun 2019 5:10 pm
RNS
Director/PDMR Shareholding
07 Jun 2019 7:00 am
RNS
FDA approval for Nucala self-administration
04 Jun 2019 8:00 am
RNS
CHMP positive on GSK's Nucala self-administration
03 Jun 2019 2:31 pm
RNS
Total Voting Rights
24 May 2019 10:54 am
RNS
Director/PDMR Shareholding
20 May 2019 1:44 pm
RNS
Director/PDMR Shareholding
13 May 2019 5:44 pm
RNS
Block listing Interim Review
  4:19 pm
RNS
Director/PDMR Shareholding
08 May 2019 6:23 pm
RNS
Result of AGM & GM
02 May 2019 5:07 pm
RNS
Trelegy Ellipta asthma study met primary endpoint
01 May 2019 3:11 pm
RNS
Director/PDMR Shareholding
  2:32 pm
RNS
Total Voting Rights
  12:00 pm
RNS
1st Quarter Results
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t